We are international
Donate
TEXT SIZE   

DARZALEX™(daratumumab) is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent.

For more information about Darzalex please visit their website www.darzalex.com

Webcasts
General Information
News & Press Releases
Will any of the newly FDA-approved drugs be available for frontline therapy?

In this week's video, Dr. Brian Durie discusses if the newly FDA-approved drugs (Ninlaro, Emplicity, Darzalex) be available for frontline therapy?

Bottom Line:

When to use the new drugs requires a case-by-case discussion, with possible use in early disease stages.


What should we know about FDA approval of Darzalex® (daratumumab)?

In this week's video, Dr. Brian Durie discusses the first monoclonal antibody approved for myeloma treatment - Darzalex (daratumumab). 

Bottom  Line:

Darzalex is a useful drug that has some drawbacks in terms of testing


Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Dr. Saad Usmani
Levine Cancer Institute
Charlotte, NC